In this video presentation, Avacta’s Chief Executive Officer Alastair Smith describes how a lateral flow rapid test works.
Avacta Group Plc (LON:AVCT) offers reagents and therapeutics based on Affimer technology for diagnostic and research applications in the United Kingdom. The company’s custom Affimer products are also used in drugs and biomarkers discovery in biotech research and development.
Avacta Group plc (LON:AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, has provided a business update for the 12 months ended 31 December 2020 and post-period. Preliminary results for the financial year ended
Avacta Group plc (LON:AVCT), the developer of Affimer® biotherapeutics and reagents, has announced that it has received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) for its Clinical Trial Authorisation (CTA) in the UK for a phase I
Avacta Group plc (LON:AVCT) CEO Alastair Smith joins DirectorsTalk to discuss first clinical evaluation of lateral flow antigen test. Alastair talks us through the data and explains the next steps in taking the test to market.
Avacta Group plc (LON:AVCT) CEO Alastair Smith joins DirectorsTalk to discuss its partnership with Mologic. Alastair talks us through the details of the agreement, expands on the additional manufacturing capacity, explains how it will develop develop other
Regarding a recent aggregated news article published earlier today, which has since been taken down, this was an error on the DirectorsTalk part linking to old news. This was nothing to do with Avacta Plc. The
UK-based Avacta Group (AIM: AVCT) has entered into a license agreement with Canadian firm POINT Biopharma to provide access to Avacta’s pre|CISION technology for the development of tumor-activated radiopharmaceuticals. The radiopharmaceutical market is expected to grow
Avacta Group, the developer of innovative cancer therapies, has entered into a license agreement with Point Biopharma to provide access to Avacta’s technology for the development of tumour-activated radiopharmaceuticals. Radiopharmaceutical therapy is now seen as a
Avacta Group plc (LON:AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISIONTM platforms, has announced that it has entered into a license agreement with POINT Biopharma Inc., to provide access to Avacta’s
Accurately identifying changes in community COVID-19 infections through wastewater surveillance is moving closer to reality. A new study, published in Environmental Science & Technology, identifies a method that not only detects the virus in wastewater samples but also
Hopes for clinical trial of tumour targeting drug by Avacta. The company has filed an application for phase one testing, for its pre|CISION prodrug AVA6000. If approved, it will be tested on patients with metastatic solid tumours. The
Avacta Group plc (LON:AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISIONTM platforms, has announced that it has submitted a Clinical Trial Application (CTA) in the UK for a Phase 1, first-in-human,
Gamma Biosciences, a life sciences tools platform created by KKR, has announced a licensing agreement between Astrea Bioseparations, a leader in affinity chromatography and bioseparations, and Avacta, a developer of innovative cancer therapies and diagnostics based
Avacta Group plc (LON:AVCT) CEO Alastair Smith joins DirectorsTalk to discuss the agreement with Astrea Bioseparations. Alastair explains what affinity separation is, tell us about the market, the details of the deal, how it fits in with
Avacta Group plc (LON:AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISIONTM platforms, has announced that it has entered into a license agreement with Astrea Bioseparations for the use of the
The finalists in the 2020 Cambridge Independent Science and Technology Awards can now be revealed. Following hundreds of entries, a shortlist across 14 categories has been drawn up. Biotech Company of the Year Covid-19 Response Award, sponsored by
Avacta Group has announced progress in the development of a highly scalable manufacturing process for a lateral flow SARS-CoV-2 antigen test being carried out with BBI Solutions, and that the lateral flow test has very good
U.K.-based Avacta Group announced significant progress in the development of a highly scalable manufacturing process for a lateral flow SARS-CoV-2 antigen test being carried out with BBI Solutions, and that the lateral flow test has very good analytical
Cambridge biotech Avacta Group is in discussions with commercial partners to establish a route to market for a CE marked BAMS COVID-19 test that can be deployed in hospitals in the UK and Europe. It is
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.